In the beginning, we focused on the contract manufacturing of medicinal products and medicines and technological development, as well as taking part in the development of several medicines and medicinal products as collaborating experts.
Our company received its pharmaceutical manufacturing licence, enabling us to win the right to manufacture a cholesterol-reducing medicinal product on a contract basis, an important step in the history of the company. Following this, we purchased the licence to manufacture several medicines that the larger pharmaceutical companies sold off as being unprofitable. We began developing generic products for multinational companies, taking care as well of the all the documentation needed for their registration.
We signed a long-term lease-work contract with the Swiss pharmaceutical company Ciba-Geigy for the primary and secondary packaging of their products; after its merger with Sandoz, we became the Hungarian representative of the new, giant company that formed, Novartis. Within the framework of this collaboration, we developed our packaging division to the highest technical standards; in keeping with our contracting party's strict quality policy, we run this division to the highest professional standards.
We formed our own research and development division.
We signed a lease-work contract with Merck AG.
We brought the first product we ourselves had developed onto the market, the Memoril 800/1200 mg tablet, a prescription product containing Piracetam, which we then marketed within a promotional collaboration undertaken with the multinational company UCB SA. A significant part of our revenues still comes from this product today.
We signed a lease-work contract with Astra-Zeneca.
We introduced the Nasopax dosing-valve nasal spray for children and adults. The medication was the fruit of a 10-year research collaboration with the 2nd Paediatrics Clinic of the Semmelweis University in Budapest. Nasopax® nasal spray contains a combination of an active ingredient that reduces the swelling of the nasal mucosae (oxymetazoline hydrochloride) and a mucolytic (bromhexine hydrochloride).
We signed a lease-work contract with Torrex Pharma, and also inaugurated a new storage warehouse with a capacity of more than 600 pallets and a storage capacity of 40 pallets for those materials needing cool-store.
We signed a lease-work contract with Roche.
We inaugurated an automated production line for tablet counting and bottle filling. At the end of the year, using funds obtained from a successful application to the Széchényi Plan, we purchased an IMA GS HT/F300 coating machine, thereby expanding our capacity to manufacture solid medicines
The National Institute for Pharmacy (OGYI) registered the Vition capsule as a non-prescription medication. Vition contains 'cell-building' ions – potassium, magnesium, zinc and phosphate – in an easily-absorbed form. In recognition of over 20 years of work by the cardiologist and Head of Internal Medicine Dr. András Sikter, VITION won the Genius Prize at the 4th GENIUS International Invention Fair in 2002 as an original Hungarian medicine.
We built up our wholesale storage warehouse, receiving our wholesale pharmaceutical licence at the same time. We successfully registered the Myderison 50/150 mg tablet, a prescription medicine containing tolperisone hydrochloride.
With an eye on the development of our factory and the business management and economic trends of the time, we introduced the SAP Business-one business management system.
We renovated our analytical and development laboratory.
We developed a medicine containing tolperisone hydrochloride for Hexal AG GmbH.
We successfully registered a medicine containing tolperisone hydrochloride that we developed for STADA, ALIUD and Mylan dura in Germany as part of the MRP process.
We successfully completed registration of the Mycosil 150 mg capsule, which contains the active ingredient flukonazol.